Dr Camille Ettelaie's Projects (13)

Biochemical Society Summer Vacation Studentship Jun 1, 2024 - Jul 31, 2024
Biochemical Society Summer Vacation Studentship for Sarah Bishop

Wolfson Equipment bid 2023 - Confocal Imaging ZEISS Elyra 7 with Lattice SIM² Oct 1, 2024 - Sep 30, 2029

ACF 2023-2026 Sep 1, 2023 - Aug 31, 2026

TEM-PAC 2: Study of Tumour Regulatory Molecules as Markers of Malignancy in Pancreatic Cystic Lesions - Maraveyas Sep 1, 2024 - Aug 31, 2025

TEM-PAC 2: Study of Tumour Regulatory Molecules as Markers of Malignancy in Pancreatic Cystic Lesions - Ettelaie Jan 1, 2024 - Dec 31, 2024

TEM-PAC 2: Study of Tumour Regulatory Molecules as Markers of Malignancy in Pancreatic Cystic Lesions - Nikitenko Jan 1, 2024 - Jun 30, 2025

RISE: Establishing super-Resolution Imaging in Hull for impactful multimorbidity ReSEarch MRC Equipment bid 2024 - Confocal Imaging ZEISS Elyra 7 with Lattice SIM² Oct 1, 2024 - Sep 30, 2029

Molecular pathways of pancreatic cancer carcinogenesis from pancreatic cystic neoplasms to adenocarcinoma Sep 1, 2020 - Aug 31, 2023
Pancreatic cancer is one of the main research areas of expertise of Professor Maraveyas and his team. This is an exciting opportunity to work on molecular pathways in pancreatic tissue that reflect the early changes during carcinogenesis and transla... Read More about Molecular pathways of pancreatic cancer carcinogenesis from pancreatic cystic neoplasms to adenocarcinoma.

Consumables for PhD project Study of Tumour Regulatory Molecules as Markers of Malignancy in Pancreatic Cystic Lesions (TEM-PAC) Feb 1, 2021 - Jul 31, 2026

Differentiating the malignant potential of pancreatic cysts Oct 1, 2017 - Dec 31, 2022
The effective diagnosis of pancreatic cancer is often quite challenging, due to a lack of disease-specific symptoms, resulting in the majority of patients presenting with advanced disease, with an associated dismal prognosis. Earlier detection of pan... Read More about Differentiating the malignant potential of pancreatic cysts.

A study of the incorporation and release of tissue factor as cancer cell-derived microparticles. Aug 1, 2014 - Jul 31, 2017

Can prevention of the activation of PAR2 prevent the release of procoagulant microvesicles from cancer cells, reduce the risk of VTE and contain the deterioration of the vasculature? Jul 1, 2015 - Jun 30, 2020
The study aims to demonstrate the indirect effect of Apixaban on suppressing the release of pro-inflammatory, pro-coagulant tissue factor-containing microvesicles, by inhibiting factor Xa and preventing the activation of PAR2. The study also demonstr... Read More about Can prevention of the activation of PAR2 prevent the release of procoagulant microvesicles from cancer cells, reduce the risk of VTE and contain the deterioration of the vasculature?.

Bridging grant for Research PhD student Nov 1, 2017 - Apr 18, 2018
The fund is to support the stipend and some of the fees incurred to bridge the funding for the PhD student.